Injectable Gels for Tissue Augmentation

用于组织增强的注射凝胶

• 批准号: 9005224
• 负责人: Michael Douglas House
• 金额: $ 36.78万
• 依托单位: TUFTS UNIVERSITY MEDFORD
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-20 至 2020-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9005224
• 关键词: Address; Animals; Behavior; Binding; Biochemical; Biocompatible Materials; Biodegradation; Biological; Biological Process; Biomechanics; Brain; Cells; Cervical; Clinical; Clinical Medicine; Collagen; Data; Dermis; Digestion; Elastomers; Environment; Extracellular Matrix; FDA approved; Family; Fibroblasts; Filler; Gel; Generic Drugs; Goals; Growth; Human; Hydrogels; Imagery; In Vitro; Inflammation; Injectable; Injection of therapeutic agent; Kinetics; Location; Matrix Metalloproteinases; Mechanics; Modeling; Molecular Weight; Natural regeneration; Oryctolagus cuniculus; Outcome; Peptide Hydrolases; Peptides; Performance; Peroxidases; Peroxides; Polymers; Pregnancy; Premature Birth; Prevention; Progesterone; Property; Proteins; RGD (sequence); Reaction; Reaction Time; Silk; Structure; System; Time; Tissues; Tyrosine; base; biomaterial compatibility; clinical application; crosslink; cytokine; design; elastomeric; functional outcomes; improved; in vivo; insight; macrophage; meetings; pregnant; prevent; public health relevance; reaction rate; repaired; reproductive; response; soft tissue; tissue reconstruction; tissue regeneration; urinary; vocal cord

 DESCRIPTION: Safe, injectable, elastomeric biomaterials to augment tissue volume and improve biomechanical functions during tissue regeneration remain as a significant clinical need. One example is preterm birth, which occurs in greater than 500,000 pregnancies per year, or 12.3% of all pregnancies in the U.S., and for which there remain poor clinical options. To address this need, in our recent studies we have developed a new family of silk protein-based elastomers with an extraordinary range of mechanical features and based on an FDA approved material. The features of these protein elastomers include tunable mechanics, tunable biodegradation, biocompatibility and options for growth factor decoration, suggesting a suitable match to the needs in the field of soft tissue augmentation. The hypothesis is that modulating silk elastomer formation and functionalization can provide a new family of injectable elastomers to meet a broad range of tissue augmentation needs, such as for the treatment of preterm birth. The planned studies build on our extensive preliminary data, with both fundamental biomaterials studies planned, combined with a targeted clinical application where new options are a current critical need. The goal is to restore cervical tissue functions and prevent preterm birth in instances where dysfunctional cervical tissue is the cause. The three Aims focus on optimizing the biomaterial properties to match mechanics, injectability and kinetics, in vitro assessments of mechanical and biological functions, and in vivo studies of cervical augmentation in a rabbit model.

 描述：用于增加组织体积并改善组织再生过程中的生物力学功能的安全、可注射、弹性生物材料仍然是临床的重要需求。一个例子是早产，每年有超过 500,000 例妊娠发生早产，占美国所有妊娠的 12.3%，而针对早产的临床选择仍然很差。为了满足这一需求，在我们最近的研究中，我们开发了一系列基于丝蛋白的弹性体，具有一系列非凡的机械特性，并且基于 FDA 批准的材料。这些蛋白质弹性体的特点包括可调节的力学、可调节的生物降解、生物相容性和生长因子装饰的选择，表明适合软组织增强领域的需求。假设是，调节丝弹性体的形成和功能化可以提供一个新的可注射弹性体家族，以满足广泛的组织增强需求，例如用于治疗早产。计划中的研究建立在我们广泛的初步数据的基础上，计划进行基础生物材料研究，并结合当前迫切需要新选择的有针对性的临床应用。目标是恢复宫颈组织功能并防止因宫颈组织功能障碍引起的早产。这三个目标侧重于优化生物材料特性以匹配力学、可注射性和动力学、机械和生物功能的体外评估以及兔模型中颈椎增强的体内研究。